Endocan, as an endothelial cell damage marker, plays role in several cardiovascular and non-cardiovascular diseases. This systematic review and meta-analysis evaluates the role of endocan as a potential diagnostic or prognostic biomarker for obstructive sleep apnea (OSA). International databases including PubMed, Embase, Web of Science, and Scopus were searched for relevant studies assessing endocan levels in OSA patients compared with healthy controls or within different severities or comorbidities of OSA. Random-effect meta-analysis was performed in order to calculate the standardized mean difference (SMD) and 95% confidence interval (CI) of serum/plasma endocan in all comparisons. A total of 10 studies were included in our systematic review, among which seven were used in meta-analysis. Meta-analysis showed that endocan levels were significantly higher in patients with OSA compared with healthy controls (SMD 1.29, 95% CI 0.64–1.93, P < .001) and this was not different between serum and plasma subgroups. However, there was no statistical difference between severe and non-severe OSA patients (SMD .64, 95% CI −.22 to 1.50, P = .147). Considerably, higher endocan levels in patients with OSA in comparison with non-OSA individuals might have clinical implications. This association warrants further research due to its potential use as a diagnostic and prognostic biomarker.
KatoMRoberts-ThomsonPPhillipsBG, et al.Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation. 2000;102:2607-2610.
7.
SchulzRSchmidtDBlumA, et al.Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax. 2000;55:1046-1051.
8.
ZengSLiSTangQ, et al.Association of matrix metalloproteinase-9 and nitric oxide with hypertension in obstructive sleep apnea. Laryngoscope Investig Otolaryngol. 2022;7:885-893.
9.
BingolZKoseMPıhtılıA, et al.Serum endothelial cell specific molecule-1 (endocan) levels in patients with obstructive sleep apnea. Biomark Med. 2016;10:177-184.
10.
LeiteARBorges-CanhaM, et al.Novel biomarkers for evaluation of endothelial dysfunction. Angiology. 2020;71:397-410.
11.
ZhaoTKechengYZhaoX, et al.The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltim)2018; 97: e13407.
12.
KhalajiABehnoushAHSaeedianB, et al.Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15:102.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
15.
WellsGASheaBO’ConnellD, et al.The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Oxford, 2000.
16.
LuoDWanXLiuJTongT. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785-1805.
17.
WanXWangWLiuJTongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
18.
HigginsJPThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions: John Wiley & Sons, 2019.
19.
RückerGSchwarzerG. Beyond the forest plot: The drapery plot. Res Synth Methods. 2021;12:13-19.
20.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
21.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629-634.
22.
AltintasNMutluLCAkkoyunDC, et al.Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology. 2016;67:364-374.
23.
KanbayACeylanEKöseoğluH, et al.Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome. Clin Respir J. 2018;12:84-90.
24.
PusurogluHSomuncuUBolatI, et al.Assessment of the relationship between endocan and obstructive sleep apnea severity. Arch Med Sci. 2020;16:1346-1352.
25.
SunHFangFLiK, et al.Circulating ESM-1 levels are correlated with the presence of coronary artery disease in patients with obstructive sleep apnea. Respir Res. 2019;20:188.
26.
SunHZhangHLiK, et al.ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234:1512-1521.
27.
SunHDuYZhangL, et al.Increasing circulating ESM-1 and adhesion molecules are associated with earlystage atherosclerosis in OSA patients:A cross-sectional study. Sleep Med. 2022;98:114-120.
28.
TurnbullCDRossiVASanterP, et al.Effect of OSA on hypoxic and inflammatory markers during CPAP withdrawal: Further evidence from three randomized control trials. Respirology. 2017;22:793-799.
29.
WenWWNingYZhangQ, et al.TNFRSF11B: A potential plasma biomarker for diagnosis of obstructive sleep apnea. Clin Chim Acta. 2019;490:39-45.
30.
YazanSKarakurtHPüşüroğluH. Relationship between obstructive sleep apnea severity and serum endocan levels in patients with hypertension. Tex Heart Inst J. 2023;50:e217664.
31.
NowakNEnglerAThielS, et al.Validation of breath biomarkers for obstructive sleep apnea. Sleep Med. 2021;85:75-86.
32.
OrrùGStorariMScanoA, et al.Obstructive Sleep Apnea, oxidative stress, inflammation and endothelial dysfunction-An overview of predictive laboratory biomarkers. Eur Rev Med Pharmacol Sci. 2020;24:6939-6948.
33.
BencharitSRedenzRGBrodyERChiangH. Salivary biomarkers associated with obstructive sleep apnea: a systematic review. Expert Rev Mol Diagn. 2021;21:223-233.
34.
KhalajiABehnoushAH, et al.Association between brain-derived neurotrophic factor levels and obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath. 2022;27:829-841.
35.
KhalajiAAmirkhaniNSharifkashaniSBehnoushAH. Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath. 2023;37129844.
36.
Kheirandish-GozalLGozalD. Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. Int J Mol Sci. 2019;20:459.
37.
LiuXMaYOuyangR, et al.The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. J Neuroinflammation. 2020;17:229.
38.
QianXYinTLiT, et al.High levels of inflammation and insulin resistance in obstructive sleep apnea patients with hypertension. Inflammation. 2012;35:1507-1511.
39.
LiXZhangXHouX, et al.Obstructive sleep apnea-increased DEC1 regulates systemic inflammation and oxidative stress that promotes development of pulmonary arterial hypertension. Apoptosis. 2022;3:432-446.
40.
KechagiaMPapassotiriouIGourgoulianisKI. Endocan and the respiratory system: a review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-3187.
41.
BéchardDGentinaTDeleheddeM, et al.Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276:48341-48349.
42.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25-37.
43.
BaltaSMikhailidisDPDemirkolS, et al.Endocan: A novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339-343.
44.
AkbogaMKDemirtasKYaylaCUnalS. Is endocan an inflammatory marker or an angiogenic marker, or both or none?Angiology. 2018;69:87.
45.
KhalajiAAmirkhaniNSharifkashaniS, et al.Systematic review of endocan as a potential biomarker of COVID-19. Angiology. 2023;21:33197231152941.
46.
HoyosCMMelehanKLLiuPY, et al.Does obstructive sleep apnea cause endothelial dysfunction? A critical review of the literature. Sleep Med Rev. 2015;20:15-26.
47.
El SolhAAAkinnusiMEBaddouraFHMankowskiCR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med. 2007;175:1186-1191.
KohlerMStradlingJR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol. 2010;7:677-685.
50.
KlisićAKavarićNSpasojević-KalimanovskaVKotur-StevuljevićJNinićA. Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population. J Med Biochem. 2021;40:41-48.
51.
DallioMMasaroneMCaprioGG, et al.Endocan serum levels in patients with non-alcoholic fatty liver disease with or without type 2 diabetes mellitus: a pilot study. J Gastrointestin Liver Dis. 2017;26:261-268.
52.
BoyukBCetinSIErmanH, et al.Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients. Arch Med Sci Atheroscler Dis. 2020;5:e290-e296.
53.
WangYLinYNZhangLY, et al.Changes of circulating biomarkers of inflammation and glycolipid metabolism by CPAP in OSA patients: a meta-analysis of time-dependent profiles. Ther Adv Chronic Dis. 2022;13:20406223211070919.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
